Literature DB >> 30425230

Authors' Response.

Nusrat Shafiq1, Vikas Gautam2, A K Pandey1, Navjot Kaur1, Shubha Garg2, H Negi1, Sharonjeet Kaur1, Pallab Ray2, S Malhotra1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30425230      PMCID: PMC6251257          DOI: 10.4103/0971-5916.245302

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
We appreciate the interest shown by Birajdar et al1 in our meta-analysis2. They acknowledge that such meta-analyses are of considerable importance in guiding policy. In fact, it was driven by a question which arose during antimicrobial stewardship activities, i.e., significance of procalcitonin based decision in different settings within a hospital. For the first point raised by Birajdar et al1 wherein they say that only one study was available for ward setting and hence was not amenable to meta-analyses, we could agree no less. However, readers would know that RevMan, the software used for the meta-analyses represents the data for subgroup analyses, whether or not data have been pooled for the subgroup. It can easily be deciphered from the Forest plot (Fig. 2)2, the confidence interval was the same as that shown in the individual study. The data for this single study, however, need to be entered and depicted to enable overall pooling which is represented at the end of the Figure 1. In fact, deleting this information would not only have flawed meta-analysis but also rendered the Forest plot incomplete. However, one does conclude that more ward based studies need to be done. The reason for difference in the number of studies for different outcomes was because not all studies reported this outcome. This again, is more of a norm than exception. As regards to the method of quality assessment, the authors need to refer to the section on Quality Assessment2 wherein the method has been referenced and explained briefly. Heterogeneity was assessed and wherever it was significant, appropriate model was used. The details of the same could have been added in the methods section. However, we thought that the Forest Plots would be self explanatory. Sensitivity analyses based on the putative causes of heterogeneity were not planned a priori and was not presented in the paper. However, the suspected reasons for clinical heterogeneity have been commented upon in the discussion section2. As far as meta-regression is concerned we would have needed to specifically address a factor or a set of factors for seeing impact on outcome. For our current analysis we did not undertake meta-regression knowing the shortcomings of post-hoc selection of variables3. It would be interesting to see someone undertake this exercise. Birajdar et al1 referred to two meta-analyses with stricter inclusion criteria45. One of these4 was available at the time of submission of our meta-analysis and was referenced. The other one5 was published later. In the latter meta-analysis5, within critically ill patients, the focus of infection has been specified or not specified. There are more specific examples, which readers may have referred to. Studies with tighter inclusion criteria would affect heterogeneity favourably. Our meta-analysis was directed towards a very pragmatic decision making exercise during management in a hospital settings. Infections of various kinds are addressed in emergency, wards and intensive care units. Regarding the Table of all included studies, we would agree as it is an important aspect of the study. However, in the past, we have had the experience of having been asked to either delete it or present it as an appendix as the journals are hard pressed for space. We have given the reference of the included studies. Regarding the conclusive remark regarding challenge of ‘lumping and splitting studies for meta-analysis’, Ioannidis et al6 who used these term explained at length the “difference in opinion of reviewers” to be an important determinant of whether to pool or not pool the data. In fact they made a case for pooling the data using appropriate methodology in case heterogeneity was present6. We refrained ourselves from undertaking a meta-analysis when we are convinced any exercise in pooling would be logically and logistically flawed7.
  7 in total

1.  How should meta-regression analyses be undertaken and interpreted?

Authors:  Simon G Thompson; Julian P T Higgins
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections.

Authors:  Hui Li; Yi-Feng Luo; Timothy S Blackwell; Can-Mao Xie
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

Review 3.  Reasons or excuses for avoiding meta-analysis in forest plots.

Authors:  John P A Ioannidis; Nikolaos A Patsopoulos; Hannah R Rothstein
Journal:  BMJ       Date:  2008-06-21

4.  Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis.

Authors:  Hui-Bin Huang; Jin-Min Peng; Li Weng; Chun-Yao Wang; Wei Jiang; Bin Du
Journal:  Ann Intensive Care       Date:  2017-11-22       Impact factor: 6.925

Review 5.  Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates.

Authors:  Nusrat Shafiq; Samir Malhotra; Vikas Gautam; Harpreet Kaur; Pravin Kumar; Sourabh Dutta; Pallab Ray; Nilima A Kshirsagar
Journal:  Indian J Med Res       Date:  2017-03       Impact factor: 2.375

6.  Procalcitonin-guided antibiotic usage - addressing heterogeneity in meta-analysis.

Authors:  Amit Ravindra Birajdar; Urmila M Thatte; Nithya J Gogtay
Journal:  Indian J Med Res       Date:  2018-09       Impact factor: 2.375

Review 7.  A meta-analysis to assess usefulness of procalcitonin-guided antibiotic usage for decision making.

Authors:  Nusrat Shafiq; Vikas Gautam; Avaneesh Kumar Pandey; Navjot Kaur; Shubha Garg; Harish Negi; Sharonjeet Kaur; Pallab Ray; Samir Malhotra
Journal:  Indian J Med Res       Date:  2017-11       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.